Yamo Pharmaceuticals LLC has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents with autism spectrum disorder (ASD).
Yamo Pharmaceuticals has enrolled and dosed the first subject in a Phase II clinical trial of L1-79 in adolescents and young adults with autism spectrum disorder (ASD).
New York, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, a clinical stage pharmaceutical company developing a novel therapy for the core symptoms of autism spectrum disorder (ASD), today announced that the first patient has been treated in a Phase 2 study of L1-79 in adolescents and young adults with ASD at six U.S. research centers of excellence. L1-79 is a tyrosine hydroxylase inhibitor designed to improve the socialization and communication symptoms by modulating the catecholaminergic pathways implicated in ASD.